An observational study in Total Knee Arthroplasty and Venous Insufficiency of Leg, sponsored by Ankara Etlik City Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-15.
Sponsored by Ankara Etlik City Hospital · Observational
The goal of this clinical trial is to find out the efficacy of diosmin and hesperidin on postoperative early rehabilitation after primary total knee arthroplasty. The main questions it aims to answer are:
Does diosmin and hesperidin combined drug decreases the lower extremity swelling, pain and increases the range of motion after primary total knee arthroplasty surgery compared to standard therapy group? Does diosmin and hesperidin combined drug decreases inflammation after total knee arthroplasty surgery.
Participants will take diosmin and hesperidin in addition to standard therapy for 14 days after total knee arthroplasty surgery. Lower extremity swelling, pain and range of motion of the patients will be recorded in every visit.
3,439 studies on the registry are indexed under Inflammation; 629 are open to participants now.
This study's enrollment of 190 is above the median of 95 across 895 observational studies indexed under Inflammation.
Browse Inflammation studies →Ankara Etlik City Hospital is the lead sponsor of 166 studies on the registry; 75 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study included patients who underwent unilateral total knee arthroplasty.
Exclusion Criteria:
Participants will take diosmin and hesperidin combination in addition to standard therapy for 14 days after total knee replacement surgery.
Drug: Diosmin and Hesperidin Combination
Participants will only take standard therapy for 14 days after total knee replacement surgery.
Participants will take diosmin and hesperidin combination for 14 days after total knee replacement surgery.
Lower extremity swelling
Lower extremity swelling is measured by measuring extremity diameters from 3 points (below patella, patella and above patella) and noted. Then percentage of increment or decrement of diameters is measured.
Time frame: From enrollment to the end of the treatment at 2 weeks
Pain
The Visual Analog Scale is used to describe patients' pain. It is a scale that describes pain by giving numbers from 0 to 10. 0 means no pain and 10 means extreme pain.
Time frame: From enrollment to the end of the treatment at 2 weeks
Range of motion
Knee range of motion is measured with goniometer.
Time frame: From enrollment to the end of the treatment at 2 weeks
Blood C-reactive protein value as an inflammotory marker
Time frame: From enrollment to the end of the treatment at 2 weeks
Blood erythrocyte sedimentation rate as an inflammotory marker
Time frame: From enrollment to the end of the treatment at 2 weeks
Blood neutrophil/lymphocyte rate as an inflammatory marker
Time frame: From enrollment to the end of the treatment at 2 weeks
Panimmune value (neutrophil x platelet x monocyte / lymphocyte) as an inflammatory marker
Time frame: From enrollment to the end of the treatment at 2 weeks
The systemic immune-inflammation index (neutrophils × platelets/lymphocytes) as an inflammatory marker
Time frame: From enrollment to the end of the treatment at 2 weeks
Plan to share: Undecided
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ankara Etlik City Hospital